What's new? Log in Free sign up

Collegium Pharmaceutical (COLL) News and press releases

Company Profile

News

From Benzinga Pro

Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $35 Price Target

News, Price Target, Reiteration, Analyst Ratings

Needham analyst Serge Belanger reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and maintains $35 price target.

Collegium Pharmaceutical Q4 EPS $1.09 Beats $(0.14) Estimate, Sales $129.62M Beat $125.19M Estimate

Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $(0.14) by 878.57 percent. This is a 313.73 percent increase over losses of $(0.51) per

Earnings Scheduled For February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Earnings Outlook For Collegium Pharmaceutical

Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $35 Price Target

News, Price Target, Reiteration, Analyst Ratings

Needham analyst Serge Belanger reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and maintains $35 price target.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Needham Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $35

News, Price Target, Analyst Ratings

Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and raises the price target from $34 to $35.

Press releases

From Benzinga Pro

Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

Earnings, News, Press Releases

– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – – Ended 2022 with Cash Balance of $173.7 Million – – Reaffirmed 2023 Financial Guidance – – Conference Call Scheduled for

Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering

News, IPOs, Press Releases

STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes

Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering

News, Financing, Press Releases

STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount

Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results

-Results at or above high-end of 2022 earnings guidance- -Final fourth quarter and full year 2022 financial results to be announced after market closes on Thursday, February 23- STOUGHTON, Mass., Feb. 06,

Collegium Provides 2023 Financial Guidance

Health Care, Press Releases

– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million – – Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million – – Adjusted EBITDA* Expected in

Mike Heffernan appointed Chairman of NMD Pharma's Board of Directors

Mike Heffernan appointed Chairman of NMD Pharma's Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has overseen several

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.